Please login to the form below

Not currently logged in
Email:
Password:

UCB to sell Biogen Idec’s MS drugs in Asia

Includes Tysabri and Tecfidera
UCB

UCB will sell Biogen Idec's portfolio of multiple sclerosis (MS) and haemophilia treatments in several Asian countries as part of a new agreement between the companies.

The deal allows UCB to commercialise the medicines in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, while both partners will develop and commercial products in China.

Drugs included as part of the deal include the huge-selling Tysabri (natalizumab), which Biogen Idec gained full rights to last year after buying out partners Elan.

Tecfidera, which is Biogen Idec's entry into the new market for oral MS drugs, is also included in the deal and is well on its way to blockbuster status after being approved in the US at the beginning of 2013.

Outside MS, Biogen Idec's two haemophilia treatments – Eloctate and Alprolix - can also be commercialised by UCB in the specified Asian markets.

Biogen Idec's senior VP, emerging markets, Carlos Dourado said: “Our goal is to bring our innovative therapies to patients around the world as quickly and efficiently as possible.

"By leveraging UCB's extensive resources, expertise and infrastructure in Asia, we believe we can grow our footprint in critical Asian markets, get our therapies to patients more quickly and create a foundation for further commercial success in this region."

US-based Biogen Idec's previosu experience in the Asian market includes a biosimialrs joint venture with Korea's Samsung Biologics known as Samsung Bioepis.

Article by
Thomas Meek

31st January 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

brian smith science of the deal
The science of the deal
Business development is more like child-raising than you might think...
The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...

Infographics